Q3 2019 Evelo Biosciences Inc Earnings Call Transcript
Good morning, and welcome to Evelo's conference call to discuss the interim clinical data from its Phase Ib trial of EDP1815. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
At this time, I'd like to turn the call over to Jessica Cotrone of Evelo. Please proceed.
Thank you, operator. This morning, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.evelobio.com under the Investors tab.
Today on our call, Simba Gill, Chief Executive Officer; Duncan McHale, Chief Medical Officer; and Mark Bodmer, President of R&D and Chief Scientific Officer, will review the positive interim clinical data for EDP1815 and discuss its significance for our strategy and future development plans.
Before we begin, I would like to remind everyone that statements made during this conference call that do not
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
